Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies - PubMed (original) (raw)
Randomized Controlled Trial
. 2011 Nov;25(11):1434-52.
doi: 10.1177/0269881110382466. Epub 2010 Sep 20.
Affiliations
- PMID: 20855349
- DOI: 10.1177/0269881110382466
Randomized Controlled Trial
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Erich Studerus et al. J Psychopharmacol. 2011 Nov.
Abstract
Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1-4 oral doses of psilocybin (45-315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.
Similar articles
- Effects of psilocybin on time perception and temporal control of behaviour in humans.
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. Wittmann M, et al. J Psychopharmacol. 2007 Jan;21(1):50-64. doi: 10.1177/0269881106065859. Epub 2006 May 19. J Psychopharmacol. 2007. PMID: 16714323 Clinical Trial. - Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Grob CS, et al. Arch Gen Psychiatry. 2011 Jan;68(1):71-8. doi: 10.1001/archgenpsychiatry.2010.116. Epub 2010 Sep 6. Arch Gen Psychiatry. 2011. PMID: 20819978 Clinical Trial. - Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M. Gouzoulis-Mayfrank E, et al. Neuropsychobiology. 2002;45(4):205-12. doi: 10.1159/000063672. Neuropsychobiology. 2002. PMID: 12097810 Clinical Trial. - Psilocybin--summary of knowledge and new perspectives.
Tylš F, Páleníček T, Horáček J. Tylš F, et al. Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. doi: 10.1016/j.euroneuro.2013.12.006. Epub 2013 Dec 17. Eur Neuropsychopharmacol. 2014. PMID: 24444771 Review. - [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
Jastrzebski M, Bala A. Jastrzebski M, et al. Psychiatr Pol. 2013 Nov-Dec;47(6):1157-67. Psychiatr Pol. 2013. PMID: 25007546 Review. Polish.
Cited by
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Carbonaro TM, et al. J Psychopharmacol. 2016 Dec;30(12):1268-1278. doi: 10.1177/0269881116662634. Epub 2016 Aug 30. J Psychopharmacol. 2016. PMID: 27578767 Free PMC article. - P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.
Smigielski L, Kometer M, Scheidegger M, Stress C, Preller KH, Koenig T, Vollenweider FX. Smigielski L, et al. Hum Brain Mapp. 2020 Dec;41(17):4982-4996. doi: 10.1002/hbm.25174. Epub 2020 Aug 21. Hum Brain Mapp. 2020. PMID: 32820851 Free PMC article. Clinical Trial. - A neurobiological perspective on social influence: Serotonin and social adaptation.
Duerler P, Vollenweider FX, Preller KH. Duerler P, et al. J Neurochem. 2022 Jul;162(1):60-79. doi: 10.1111/jnc.15607. Epub 2022 Mar 31. J Neurochem. 2022. PMID: 35274296 Free PMC article. Review. - MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma.
Gabay AS, Kempton MJ, Gilleen J, Mehta MA. Gabay AS, et al. J Neurosci. 2019 Jan 9;39(2):307-320. doi: 10.1523/JNEUROSCI.1276-18.2018. Epub 2018 Nov 19. J Neurosci. 2019. PMID: 30455187 Free PMC article. Clinical Trial. - Pharmacokinetics of N,N-dimethyltryptamine in Humans.
Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, Weaver R, Allen G, Hughes C, Topping H, Bowman A, James E. Good M, et al. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):311-327. doi: 10.1007/s13318-023-00822-y. Epub 2023 Apr 22. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37086340 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources